|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find link tool for suggestions. (February 2014)|
||This article contains content that is written like an advertisement. (June 2015) (Learn how and when to remove this template message)|
Kalos has been covered by ABC News  on Good Morning America, and profiled in Business Week and Time Magazine. The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation), and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.
KT-220, the current lead drug candidate, demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.
George Colberg - Chairman & CEO
James Merritt, M.D. - President and Chief Medical Officer
Gregory F. Witchel, MBA - Executive Vice President
Daniel Von Hoff, MD, FACP - Chairman, Scientific Advisory Board
David L. Vesely, MD, PhD - Scientific Advisory Board
Marc B. Garnick, MD - Scientific Advisory Board
Patrice P Rioux, MD, PhD - Scientific Advisory Board
Derek E Vest - Secretary